Tolmar Inc.
Clinical trials sponsored by Tolmar Inc., explained in plain language.
-
Breast cancer patients monitored for years in new safety trial
Disease control By invitation onlyThis study looks at the long-term safety of a drug called TOL2506, which suppresses ovarian function, in people with hormone receptor-positive (HR+) breast cancer. It includes premenopausal women and men who already completed a previous study. Participants will take TOL2506 along…
Phase 3 • Sponsor: Tolmar Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New injection aims to halt ovarian function in breast cancer fight
Disease control OngoingThis phase 3 study tests a 3-month injection (TOL2506) to temporarily stop ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The goal is to see if it works well with hormone therapy (tamoxifen or aromatase inhibitors) to control the cancer. About 250 …
Phase 3 • Sponsor: Tolmar Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Testosterone drug JATENZO under safety spotlight for adrenal impact
Disease control OngoingThis Phase 4 study is checking whether JATENZO, a testosterone replacement drug, affects adrenal gland function in men with low testosterone (hypogonadism). About 110 men aged 18-65 will take JATENZO for 12 months. Researchers will measure cortisol levels after a stimulation test…
Phase 4 • Sponsor: Tolmar Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:07 UTC